A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma
The purpose of this study was to evaluate the efficacy and safety of tislelizumab as second line treatment in participants with advanced unresectable/metastatic ESCC that had progressed during or after first line therapy.
Key Inclusion Criteria:
Key Exclusion Criteria:
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
Huaian, Jiangsu 223002, China
Nanjing, Jiangsu 210008, China
Chengdu, Sichuan 610071, China
Hangzhou, Zhejiang 310003, China
SaintHerblain, 44805, France
Akitashi, Akita 010-8543, Japan
Osakashi, Osaka 541-8567, Japan
Suitashi, Osaka 565-0871, Japan
Takatsukishi, Osaka 569-8686, Japan
Kitaadachigun, Saitama 362-0806, Japan
Suntogun, Shizuoka 411-8777, Japan
Chuoku, Tokyo 104-0045, Japan
Kotoku, Tokyo 135-8550, Japan
HwasunGun, Jeollanam-do 58128, South Korea
Greater Manchester, M20 4BX, United Kingdom